Mustang Bio (MBIO) Projected to Release Earnings on Tuesday

Mustang Bio (NASDAQ:MBIO) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Mustang Bio to post earnings of ($140.00) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 7:00 AM ET.

Mustang Bio (NASDAQ:MBIO) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($140.00) by $139.84.

Mustang Bio Trading Down 1.8%

Shares of MBIO stock opened at $0.59 on Tuesday. The stock has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.76. Mustang Bio has a 12 month low of $0.53 and a 12 month high of $1.88. The company has a market capitalization of $4.47 million, a P/E ratio of -1.31 and a beta of 2.06.

Hedge Funds Weigh In On Mustang Bio

An institutional investor recently bought a new stake in Mustang Bio stock. DRW Securities LLC purchased a new stake in Mustang Bio, Inc. (NASDAQ:MBIO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned approximately 1.01% of Mustang Bio at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.